# Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

> **NCT02981914** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 12 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma
- B-cell Non-Hodgkin Lymphoma
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02981914
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2020-10-09
- **Final completion:** 2020-11-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981914, "Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02981914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*